Mary-Claire King, a geneticist now at the University of Washington, demonstrated in the mid-1990s that some breast and ovarian cancers are hereditary and identified mutations in BRCA1 and BRCA2 that greatly increase risk. Her work established that genetic testing could identify individuals at high risk and that clinical interventions — including prophylactic mastectomy and removal of ovaries and fallopian tubes — could substantially reduce cancer mortality for many women. King’s research bridged evolutionary genetics and medical genetics and produced an actionable pathway from discovery to clinical care.
King recounts being invited to give a seminar at the Karolinska Institutet roughly two decades ago; she later learned that such invitations are a signal that a candidate is under consideration by the Nobel Prize committee. During the visit she presented her work and met with committee members in a series of interviews. She describes the conversations as varied: some interviewers showed deep understanding of the work, while others were skeptical about whether genetics could solve the problem of cancer predisposition. The meetings were polite and professionally conducted; she received no direct feedback at the time.
King emphasizes the real-world consequences of identifying BRCA mutations. Women who test positive can choose preventive surgeries or other measures, and many have done so; these interventions have reduced cancer mortality for thousands of women. King describes the emotional resonance of patient letters and direct contacts: she shared one physical letter from a woman whose mother had died of breast cancer and who later discovered she carried a BRCA1 mutation, underwent recommended surgeries, and remained cancer-free. Such communications underscore the human impact of genetic discovery and the network of affected individuals worldwide who seek information and support.
King characterizes the Nobel selection process as narrow and stochastic. She notes the long time horizons involved and the low chance of being chosen in any given year. When Nobel announcements fall in the middle of the night in her time zone, she typically does not set an alarm because the odds of selection are very small and the outcome will still be known afterward. She recalls the year Katalin Karikó and Drew Weissman won for work enabling mRNA vaccines as unusually predictable, given the global scale of the impact. In contrast, other fields or topics may be harder to anticipate, and King speculated that GLP-1–related research could be prominent in certain years.
King observes substantial progress: women now occupy a larger share of the research workforce, senior faculty positions, and policymaking roles in health. Nonetheless, she identifies persistent structural barriers, notably the timing conflict between early career development and child-rearing. She argues that without societal measures such as structured, high-quality subsidized childcare, true equality will remain out of reach.
Her practical advice to early-career scientists is to choose problems that are important to them and that they enjoy working on daily. She emphasizes that small problems can expand into larger, impactful endeavors over time and that persistence, collaboration, and on-the-ground encouragement matter. King also stresses the importance of engagement with people affected by the research, both to inform priorities and to sustain motivation during difficult periods in a long career.
King offers an intellectual framing for her work: “genetics is a way of thinking, genomics is a set of tools.” She uses this distinction to explain how conceptual approaches from genetics can be applied to increasingly challenging questions as genomic technologies advance. That perspective informs both her public-facing communication and her technical contributions: she aims to be available to people with questions while also focusing on complex genetic problems that require specialized expertise. She cites advice from Bernie Fisher, who told her to both let the discovery go and remain available to help people — a dual role she has sought to balance.
King describes a diverse portfolio of ongoing work in her lab. Current projects reported include studies of de novo mutations in schizophrenia, investigations of expanded repeat sequences in bipolar disorder, searches for cryptic mutations and structural variations that contribute to inherited cancer predisposition, and work on congenital abnormalities. She frames these efforts as an extension of the same genetic way of thinking that led to the BRCA discoveries, now enabled by newer genomic tools that permit questions that were previously inaccessible. The lab remains engaged in both public-facing roles and technical problem-solving in human genetics.